<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>OXISTAT - oxiconazole nitrate lotion </strong><br>Rebel Distributors Corp.<br></p></div>
<h1>OXISTAT<span class="Sup">®</span> (oxiconazole nitrate cream) Cream, 1%* <br>OXISTAT<span class="Sup">®</span> (oxiconazole nitrate lotion) Lotion, 1%*</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">*Potency expressed as oxiconazole</span></p>
<p><span class="Bold">R</span><span class="Sub">x</span><span class="Bold">Only</span></p>
<p><span class="Bold">FOR TOPICAL DERMATOLOGIC USE ONLY— <br>NOT FOR OPHTHALMIC OR INTRAVAGINAL USE</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s4"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">OXISTAT<span class="Sup">®</span> (oxiconazole nitrate cream) Cream, 1% and OXISTAT<span class="Sup">®</span> (oxiconazole nitrate lotion) Lotion, 1% formulations contain the antifungal active compound oxiconazole nitrate. Both formulations are for topical dermatologic use only.</p>
<p>Chemically, oxiconazole nitrate is 2',4'-dichloro-2-imidazol-1-ylacetophenone (<span class="Italics">Z</span>)-[<span class="Italics">0</span>-(2,4-dichlorobenzyl)oxime], mononitrate.  The compound has the molecular formula C<span class="Sub">18</span>H<span class="Sub">13</span>ON<span class="Sub">3</span>CI<span class="Sub">4</span>·HNO<span class="Sub">3</span>, a molecular weight of 492.15, and the following structural formula: </p>
<div class="Figure">
<a name="f1"></a><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=094d5b1e-ccf6-4384-b208-fd70360ffda2&amp;name=oxistat-cream-lot-01.jpg">
</div>
<p>Oxiconazole nitrate is a nearly white crystalline powder, soluble in methanol; sparingly soluble in ethanol, chloroform, and acetone; and very slightly soluble in water.</p>
<p>OXISTAT<span class="Sup">®</span> Cream contains 10 mg of oxiconazole per gram of cream in a white to off-white, opaque cream base of purified water USP, white petrolatum USP, stearyl alcohol NF, propylene glycol USP, polysorbate 60 NF, cetyl alcohol NF, and benzoic acid USP 0.2% as a preservative.</p>
<p>OXISTAT<span class="Sup">®</span> Lotion contains 10 mg of oxiconazole per gram of lotion in a white to off-white, opaque lotion base of purified water USP, white petrolatum USP, stearyl alcohol NF, propylene glycol USP, polysorbate 60 NF, cetyl alcohol NF, and benzoic acid USP 0.2% as a preservative.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s5"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43682-4">
<a name="s6"></a><a name="section-3.1"></a><p></p>
<p class="First"><span class="Bold">Pharmacokinetics:</span> The penetration of oxiconazole nitrate into different layers of the skin was assessed using an in vitro permeation technique with human skin. Five hours after application of 2.5 mg/cm<span class="Sup">2</span> of oxiconazole nitrate cream onto human skin, the concentration of oxiconazole nitrate was demonstrated to be 16.2 μmol in the epidermis, 3.64 μmol in the upper corium, and 1.29 μmol in the deeper corium. Systemic absorption of oxiconazole nitrate is low. Using radiolabeled drug, less than 0.3% of the applied dose of oxiconazole nitrate was recovered in the urine of volunteer subjects up to 5 days after application of the cream formulation.</p>
<p>Neither in vitro nor in vivo studies have been conducted to establish relative activity between the lotion and cream formulations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-3.2"></a><p></p>
<p class="First"><span class="Bold">Microbiology:</span> Oxiconazole nitrate is an imidazole derivative whose antifungal activity is derived primarily from the inhibition of ergosterol biosynthesis, which is critical for cellular membrane integrity. It has in vitro activity against a wide range of pathogenic fungi.</p>
<p>Oxiconazole has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms both in vitro and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> at indicated body sites (see <a href="#s8">INDICATIONS AND USAGE</a>):</p>
<dl>
<dt> </dt>
<dd><span class="Italics">Epidermophyton floccosum</span></dd>
<dt> </dt>
<dd><span class="Italics">Trichophyton mentagrophytes</span></dd>
<dt> </dt>
<dd><span class="Italics">Trichophyton rubrum</span></dd>
<dt> </dt>
<dd><span class="Italics">Malassezia furfur</span></dd>
</dl>
<p>The following in vitro data are available; <span class="Bold Underline">however, their clinical significance is unknown</span>. Oxiconazole exhibits satisfactory in vitro <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs) against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms; however, the safety and efficacy of oxiconazole in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these organisms have not been established in adequate and well-controlled clinical trials:</p>
<dl>
<dt> </dt>
<dd><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span></dd>
<dt> </dt>
<dd><span class="Italics">Microsporum audouini</span></dd>
<dt> </dt>
<dd><span class="Italics">Microsporum canis</span></dd>
<dt> </dt>
<dd><span class="Italics">Microsporum gypseum</span></dd>
<dt> </dt>
<dd><span class="Italics">Trichophyton tonsurans</span></dd>
<dt> </dt>
<dd><span class="Italics">Trichophyton violaceum</span></dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s8"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">OXISTAT<span class="Sup">®</span> Cream and Lotion are indicated for the topical treatment of the following dermal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>: <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>, <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span>, and <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> corporis due to <span class="Italics">Trichophyton rubrum, Trichophyton mentagrophytes,</span> or <span class="Italics">Epidermophyton floccosum.</span> OXISTAT<span class="Sup">®</span> Cream is indicated for the topical treatment of <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> (pityriasis) versicolor due to <span class="Italics">Malassezia furfur</span> (see <a href="#s22">DOSAGE AND ADMINISTRATION</a> and <a href="#s23">CLINICAL STUDIES</a>).</p>
<p>OXISTAT<span class="Sup">®</span> Cream may be used in pediatric patients for <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> corporis, <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span>, <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>, and <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> (pityriasis) versicolor; however, these indications for which OXISTAT<span class="Sup">®</span> Cream has been shown to be effective rarely occur in children below the age of 12.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s9"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">OXISTAT<span class="Sup">®</span> Cream and Lotion are contraindicated in individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of their components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s10"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">OXISTAT<span class="Sup">®</span> (oxiconazole nitrate cream)Cream, 1% and OXISTAT<span class="Sup">®</span> (oxiconazole nitrate lotion) Lotion, 1% are not for ophthalmic or intravaginal use.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s11"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s12"></a><a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold">General:</span> OXISTAT<span class="Sup">®</span> Cream and Lotion are for external dermal use only. Avoid introduction of OXISTAT<span class="Sup">®</span> Cream or Lotion into the eyes or vagina. If a reaction suggesting sensitivity or chemical irritation should occur with the use of OXISTAT<span class="Sup">®</span> Cream or Lotion, treatment should be discontinued and appropriate therapy instituted. If signs of epidermal irritation should occur, the drug should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s13"></a><a name="section-7.2"></a><p></p>
<p class="First"><span class="Bold">Information for Patients:</span> The patient should be instructed to:</p>
<ol class="Arabic">
<li>Use OXISTAT<span class="Sup">®</span> as directed by the physician. The hands should be washed after applying the medication to the affected area(s). Avoid contact with the eyes, nose, mouth, and other mucous membranes. OXISTAT<span class="Sup">®</span> is for external use only.</li>
<li>Use the medication for the <span class="Bold">full</span> treatment time recommended by the physician, even though symptoms may have improved. Notify the physician if there is no improvement after 2 to 4 weeks, or sooner if the condition worsens (see below).</li>
<li>Inform the physician if the area of application shows signs of increased irritation, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, burning, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or oozing.</li>
<li>Avoid the use of occlusive dressings unless otherwise directed by the physician.</li>
<li>Do not use this medication for any disorder other than that for which it was prescribed.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s14"></a><a name="section-7.3"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions:</span> Potential drug interactions between OXISTAT<span class="Sup">®</span> and other drugs have not been systematically evaluated.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s15"></a><a name="section-7.4"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span> Although no long-term studies in animals have been performed to evaluate carcinogenic potential, no evidence of mutagenic effect was found in 2 mutation assays (Ames test and Chinese hamster V79 in vitro cell mutation assay) or in 2 cytogenetic assays (human peripheral blood lymphocyte in vitro chromosome aberration assay and in vivo micronucleus assay in mice).</p>
<p>Reproductive studies revealed no impairment of fertility in rats at oral doses of 3 mg/kg/day in females (1 time the human dose based on mg/m<span class="Sup">2</span>) and 15 mg/kg/day in males (4 times the human dose based on mg/m<span class="Sup">2</span>). However, at doses above this level, the following effects were observed: a reduction in the fertility parameters of males and females, a reduction in the number of sperm in vaginal smears, extended estrous cycle, and a decrease in mating frequency.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="s16"></a><a name="section-7.5"></a><p></p>
<p class="First"><span class="Bold">Pregnancy:</span><span class="Bold Italics">Teratogenic Effects:</span> Pregnancy Category B. Reproduction studies have been performed in rabbits, rats, and mice at oral doses up to 100, 150, and 200 mg/kg/day (57, 40, and 27 times the human dose based on mg/m<span class="Sup">2</span>), respectively, and revealed no evidence of harm to the fetus due to oxiconazole nitrate. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s17"></a><a name="section-7.6"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers:</span> Because oxiconazole is excreted in human milk, caution should be exercised when the drug is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s18"></a><a name="section-7.7"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use:</span> OXISTAT<span class="Sup">®</span> Cream may be used in pediatric patients for <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> corporis, <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span>, <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>, and <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> (pityriasis) versicolor; however, these indications for which OXISTAT<span class="Sup">®</span> Cream has been shown to be effective rarely occur in children below the age of 12.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s19"></a><a name="section-7.8"></a><p></p>
<p class="First"><span class="Bold">Geriatric Use:</span> A limited number of patients at or above 60 years of age (n ~ 396) have been treated with OXISTAT<span class="Sup">®</span> Cream in US and non-US clinical trials, and a limited number (n = 43) have been treated with OXISTAT<span class="Sup">®</span> Lotion in US clinical trials. The number of patients is too small to permit separate analysis of efficacy and safety. No adverse events were reported with OXISTAT<span class="Sup">®</span> Lotion in geriatric patients, and the adverse reactions reported with OXISTAT<span class="Sup">®</span> Cream in this population were similar to those reported by younger patients. Based on available data, no adjustment of dosage of OXISTAT<span class="Sup">®</span> Cream and Lotion in geriatric patients is warranted.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s20"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">During clinical trials, of 955 patients treated with oxiconazole nitrate  <span class="Underline">cream</span>, 1%, 41 (4.3%) reported adverse reactions thought to be related to drug therapy. These reactions included <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (1.6%); burning (1.4%); irritation and <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span> (0.4% each); <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span> (0.3%); <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (0.2%); and <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span>, fissure, maceration, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, and <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> (0.1% each).</p>
<p>In a controlled, multicenter clinical trial of 269 patients treated with oxiconazole nitrate  <span class="Underline">lotion</span>, 1%, 7 (2.6%) reported adverse reactions thought to be related to drug therapy. These reactions included burning and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> (0.7% each) and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, scaling, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="133551" conceptname="Vesicular eczema of hands and/or feet">dyshidrotic eczema</span> (0.4% each).</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s21"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">When 5% oxiconazole cream (5 times the concentration of the marketed product) was applied at a rate of 1 g/kg to approximately 10% of body surface area of a group of 40 male and female rats for 35 days, 3 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> and severe dermal <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> were reported. No <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> in humans have been reported with use of oxiconazole nitrate cream or lotion.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s22"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">OXISTAT<span class="Sup">®</span> Cream or Lotion should be applied to affected and immediately surrounding areas once to twice daily in patients with <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>, <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> corporis, or <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span>. OXISTAT<span class="Sup">®</span> Cream should be applied once daily in the treatment of <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> (pityriasis) versicolor. <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">Tinea</span> corporis, <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span>, and <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> (pityriasis) versicolor should be treated for 2 weeks and <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span> for 1 month to reduce the possibility of recurrence. If a patient shows no clinical improvement after the treatment period, the diagnosis should be reviewed.</p>
<p>Note: <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">Tinea</span> (pityriasis) versicolor may give rise to hyperpigmented or hypopigmented patches on the trunk that may extend to the neck, arms, and upper thighs. Treatment of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may not immediately result in restoration of pigment to the affected sites. Normalization of pigment following successful therapy is variable and may take months, depending on individual skin type and incidental sun exposure. Although <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> (pityriasis) versicolor is not contagious, it may recur because the organism that causes the disease is part of the normal skin flora.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s23"></a><a name="section-11"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">The following definitions were applied to the clinical and microbiological outcomes in patients enrolled in the clinical trials that form the basis for the approvals of OXISTAT<span class="Sup">®</span> Lotion and OXISTAT<span class="Sup">®</span> Cream.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-11.1"></a><p></p>
<h2>Definitions:</h2>
<ol class="Arabic">
<li>Mycological Cure: No evidence (culture and KOH preparation) of the baseline (original) pathogen in a specimen from the affected area taken at the 2-week post-treatment visit (for <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> [pityriasis] versicolor, mycological cure was limited to KOH only).</li>
<li>Treatment Success: <span class="Underline">Both</span> a global evaluation of 90% clinical improvement and a microbiologic eradication (see above) at the 2-week post-treatment visit.</li>
</ol>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-11.1.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">Tinea Pedis</span>:</span> THERE ARE NO HEAD-TO-HEAD COMPARISON TRIALS OF THE OXISTAT<span class="Sup">®</span> CREAM AND LOTION FORMULATIONS IN THE TREATMENT OF <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">TINEA PEDIS</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-11.1.2"></a><p></p>
<p class="First"><span class="Bold Italics">Lotion Formulation:</span> The clinical trial for the lotion formulation line extension involved 332 evaluable patients with clinically and microbiologically established <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>. Of these evaluable patients, 64% were diagnosed with hyperkeratotic plantar <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span> and 28% with interdigital <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>. Seventy-seven percent (77%) had disease secondary to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="Italics">Trichophyton rubrum,</span> 18% had disease secondary to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="Italics">Trichophyton mentagrophytes</span>, and 4% had disease secondary to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="Italics">Epidermophyton floccosum.</span></p>
<p>The results of this clinical trial at the 2-week post-treatment follow-up visit are shown in the following table:</p>
<a name="ic5db57f9-eb21-4f11-8f85-b28900e0d000"></a><table width="100%">
<col align="left" width="52.375%">
<col align="left" width="17.125%">
<col align="left" width="15.975%">
<col align="left" width="14.525%">
<thead>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="bottom"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="bottom">OXISTAT<span class="Sup">®</span> Lotion</td>
<td class="Rrule Toprule" align="center" valign="bottom"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Patient Outcome</td>
<td class="Botrule Rrule" align="center" valign="top">b.i.d.</td>
<td class="Botrule Rrule" align="center" valign="top">q.d.</td>
<td class="Botrule Rrule" align="center" valign="top">Vehicle</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left" valign="top">Mycological cure</td>
<td class="Rrule" align="center" valign="top">67%</td>
<td class="Rrule" align="center" valign="top">64%</td>
<td class="Rrule" align="center" valign="top">28%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Treatment success</td>
<td class="Botrule Rrule" align="center" valign="top">41%</td>
<td class="Botrule Rrule" align="center" valign="top">34%</td>
<td class="Botrule Rrule" align="center" valign="top">10%</td>
</tr>
</tbody>
</table>
<p>In this study, the improvement and cure rates of the b.i.d.- and q.d.-treated groups did not differ significantly (95% confidence interval) from each other but were statistically (95% confidence interval) superior to the vehicle-treated group.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-11.1.3"></a><p></p>
<p class="First"><span class="Bold Italics">Cream Formulation:</span> The two pivotal trials for the cream formulation involved 281 evaluable patients (total from both trials) with clinically and microbiologically established <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>.</p>
<p>The combined results of these 2 clinical trials at the 2-week post-treatment follow-up visit are shown in the following table:</p>
<a name="i898b59a8-9510-4b7c-849c-dfb136094011"></a><table width="100%">
<col align="left" width="36.750%">
<col align="left" width="26.525%">
<col align="left" width="19.300%">
<col align="left" width="17.425%">
<thead>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="bottom"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="bottom">OXISTAT<span class="Sup">®</span> Cream</td>
<td class="Rrule Toprule" align="center" valign="bottom"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Patient Outcome</td>
<td class="Botrule Rrule" align="center" valign="top">b.i.d.</td>
<td class="Botrule Rrule" align="center" valign="top">q.d.</td>
<td class="Botrule Rrule" align="center" valign="top">Vehicle</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left" valign="top">Mycological cure</td>
<td class="Rrule" align="center" valign="top">77%</td>
<td class="Rrule" align="center" valign="top">79%</td>
<td class="Rrule" align="center" valign="top">33%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Treatment success</td>
<td class="Botrule Rrule" align="center" valign="top">52%</td>
<td class="Botrule Rrule" align="center" valign="top">43%</td>
<td class="Botrule Rrule" align="center" valign="top">14%</td>
</tr>
</tbody>
</table>
<p>All the improvement and cure rates of the b.i.d.- and q.d.- treated groups did not differ significantly (95% confidence interval) from each other but were statistically (95% confidence interval) superior to the vehicle-treated group.</p>
<p>In addition, pediatric data (95 children ages 10 and under) available with the cream formulation indicate that it is safe and effective for use in children when used as directed. Adverse events were reported in 2 children; 1 child was reported to have reddening of the skin and 1 child was reported to have <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>-like skin alterations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-11.1.4"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">Tinea</span> (pityriasis) Versicolor:</span> Two pivotal clinical trials of OXISTAT<span class="Sup">®</span> Cream in <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> (pityriasis) versicolor involved 219 evaluable patients in the q day OXISTAT<span class="Sup">®</span> and vehicle arms of the trial with clinical and mycological evidence of <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> (pityriasis) versicolor. Patients were treated for 2 weeks with OXISTAT<span class="Sup">®</span> Cream once daily, or with cream vehicle. The combined results of these clinical trials at the 2-week post-treatment follow-up visit are shown in the following table. These results are based on 207 patients (110 in the OXISTAT<span class="Sup">®</span> group and 97 in the vehicle group) with efficacy evaluations at this visit.</p>
<a name="i5ac8b7aa-5245-4357-88e4-5797c5517efa"></a><table width="100%">
<col align="left" width="42.614%">
<col align="left" width="40.147%">
<col align="left" width="17.239%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="bottom"></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">OXISTAT<span class="Sup">®</span> Cream</td>
<td class="Rrule Toprule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Patient Outcome</td>
<td class="Botrule Rrule" align="center" valign="top">q.d.</td>
<td class="Botrule Rrule" align="center" valign="top">Vehicle</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Mycological cure</td>
<td class="Rrule" align="center" valign="top">88%</td>
<td class="Rrule" align="center" valign="top">67%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Treatment success</td>
<td class="Botrule Rrule" align="center" valign="top">83%</td>
<td class="Botrule Rrule" align="center" valign="top">62%</td>
</tr>
</tbody>
</table>
<p>Only once a day was shown in both studies to be statistically superior to vehicle for all efficacy parameters at 2 weeks and follow-up.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s29"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">OXISTAT<span class="Sup">®</span> (oxiconazole nitrate cream) Cream, 1% is supplied in:</p>
<dl>
<dt> </dt>
<dd>30-g tubes (NDC 21695-459-30), and</dd>
</dl>
<p><span class="Bold">Store between 15° and 30° C (59° and 86° F).</span></p>
<p><span class="Bold">PharmaDerm<span class="Sup">®</span></span><br>
A division of Nycomed US Inc.<br>
Melville, NY 11747 USA <br>
www.pharmaderm.com
</p>
<p><span class="Bold">Repackaged by:</span><br>
		Rebel Distributors Corp.<br>
		Thousand Oaks, CA 91320<br></p>
<p>
I8358C/IF8358C <br>
R2/09 <br>
#178
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<p class="First"><img alt="Package Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=094d5b1e-ccf6-4384-b208-fd70360ffda2&amp;name=459.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OXISTAT 		
					</strong><br><span class="contentTableReg">oxiconazole nitrate lotion</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:21695-459(NDC:0462-0359)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>oxiconazole nitrate</strong> (oxiconazole) </td>
<td class="formItem">oxiconazole nitrate</td>
<td class="formItem">30 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>petrolatum</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>stearyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polysorbate 60</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cetyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>benzoic acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:21695-459-30</td>
<td class="formItem">30 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020209</td>
<td class="formItem">01/25/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Rebel Distributors Corp.
							(118802834)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Rebel Distributors Corp.</td>
<td class="formItem"></td>
<td class="formItem">118802834</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0b5b9f06-15fc-432d-a891-8d91bf80f2d4</div>
<div>Set id: 094d5b1e-ccf6-4384-b208-fd70360ffda2</div>
<div>Version: 1</div>
<div>Effective Time: 20091030</div>
</div>
</div> <div class="DistributorName">Rebel Distributors Corp.</div></p>
</body></html>
